高基线IPSS男性接受前列腺SBRT的泌尿结局
本研究纳入72例基线IPSS≥15的前列腺癌患者,评估前列腺SBRT后泌尿毒性及患者报告症状严重程度变化。结果显示急性2级和3级GU毒性分别为20.8%和1.4%,晚期2级和3级分别为37.5%和5.6%,多数2级以上毒性末次随访时缓解。中位总IPSS在24±6个月时显著低于基线(18 vs 12;P < .001)。
要点
- 基线IPSS≥15者前列腺SBRT后严重GU毒性发生率低。
- 多数2级以上GU毒性至末次随访时缓解。
- 基线尿急与晚期2级以上GU毒性相关(OR 2.10)。
核心结论
- 基线IPSS≥15的男性接受前列腺SBRT后严重GU毒性发生率低,患者报告症状总体随时间改善,高基线IPSS不应阻碍临床医生提供前列腺SBRT。
研究设计与样本
- 前瞻性记录CTCAE v3.0 GU毒性和IPSS,采用单变量逻辑回归分析GU毒性潜在预测因素。
主要发现
- 存活者中位随访26.8个月,急性2级和3级GU毒性发生率分别为20.8%和1.4%。
- 晚期2级和3级GU毒性发生率分别为37.5%和5.6%,多数2级以上毒性至末次随访时缓解。
- 按CTCAE v5.0重新分级后无3级不良事件。
- 与基线相比,24±6个月时中位总IPSS显著降低(18 vs 12;P < .001),严重评分(IPSS≥20)比例从29.2%降至13.9%。
- 治疗前尿急与晚期2级以上GU毒性相关(OR 2.10;95%CI 1.33-3.31;P = .001)。
临床怎么用
- 高基线IPSS不应作为前列腺SBRT的排除标准,治疗前应告知患者泌尿症状可能随时间改善。
- 治疗前存在尿急者晚期2级以上GU毒性风险较高,需加强随访监测。
局限性
- 单中心回顾性设计,样本量较小(72例),中位随访26.8个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: There are limited data regarding high-dose stereotactic body radiation therapy (SBRT) for prostate cancer in patients with poor baseline urinary function. The purpose of this study was to evaluate genitourinary (GU) toxicity and changes in patient-reported symptom severity scores after prostate SBRT in men with a high pretreatment International Prostate Symptom Score (IPSS). METHODS AND MATERIALS: Seven hundred fifty-three patients treated with prostate SBRT at our institution from 2012 to 2019 were identified, of whom 72 consecutive patients with baseline IPSS ≥15 were selected for this study. GU toxicity according to Common Terminology Criteria for Adverse Events (CTCAE) v3.0 and IPSS were prospectively documented at each follow-up visit. Univariable logistic regression was used to evaluate for potential predictors of GU toxicity. RESULTS: Median follow-up in survivors was 26.8 months. The rates of acute grade 2 and 3 GU toxicity were 20.8% and 1.4%, respectively. The rates of late grade 2 and 3 GU toxicity were 37.5% and 5.6%, respectively. The majority of grade 2+ toxicities resolved by last follow-up, and when toxicities were regraded per CTCAE v5.0, there were no longer any grade 3 adverse events. Total IPSS and individual symptom subscores improved over time. Compared with baseline, median total IPSS at 24 ± 6 months was significantly lower (18 vs 12; P < .001) and the proportion of patients with severe scores (IPSS ≥20) decreased from 29.2% to 13.9%. Pretreatment urinary urgency was associated with late grade 2+ GU toxicity (odds ratio, 2.10; 95% confidence interval, 1.33-3.31; P = .001). CONCLUSIONS: In men with baseline IPSS ≥15 managed with prostate SBRT, the rate of severe GU toxicity was low and patient-reported symptoms generally improved over time. Thus, high pretreatment IPSS should not deter clinicians from offering prostate SBRT.
引用
- Gorovets D, Hopkins M, Goldman DA, et al. Urinary Outcomes for Men With High Baseline International Prostate Symptom Scores Treated With Prostate SBRT. Adv Radiat Oncol. 2020. PMID: 33665486. doi:10.1016/j.adro.2020.09.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。